Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BIRB 796 BS in Healthy Subjects
NCT02209805Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2001
- Primary completion
- Mar 2001
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of doramapimod (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of patients with clinically significant changes in vital signs up to 21 days, Number of patients with clinically significant changes in laboratory parameters up to 21 days and 2 more. Started Jan 2001; status: completed.
02
Drugs
doramapimod
Beyond the preview
Go deeper on NCT02209805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02209805.